VYGR

1.5304.97%
MJ

Michael J. Higgins

Independent Chairman

Mr. Michael J. Higgins, M.B.A., is Independent Chairman of the Board of Voyager Therapeutics, Inc. from March 22, 2022. He serves as an Independent Director of Cyclerion Therapeutics, Inc. since November 2023. He serves as Director of Nocion Therapeutics, Inc. since September 2020 and serves as its Chairman since 2024. He was Director of Sea Pharmaceuticals, LLC from 2015 to 2020. He served as Interim President at Voyager Therapeutics, Inc. until March 22, 2022 and served as its Interim Chief Executive Officer since June 2021 until March 22, 2022. He had been an Independent Director of Genocea Biosciences, Inc. since February 2015 until May 2022. He has been an Independent Director of Pulmatrix, Inc. since March 2015, Nocion Therapeutics, Inc., a biopharmaceutical company since May 2015. He served as Entrepreneur-in-Residence at Polaris Partners since 2015 until 2020. He served as Independent Director of CAMP4 Therapeutics Corporation since October 2017 until June 11, 2026. He serves as Independent Chairman of the Board at Pulmatrix, Inc. since April 21, 2020. Mr. Higgins has served as an Executive Chairman of KinDex Pharmaceutics, Inc., a biotechnology company, from March 2016 to March 2020 and has served as Interim Chief Executive Officer from 2016 to 2020. Mr. Higgins served as Member of Business Advisory Board of ProMIS Neurosciences, Inc. until November 2024. He has experience in the biopharmaceutical industry. He has financial and business expertise, including his diversified background as an Executive Officer in public pharmaceutical companies. He served as the Chief Operating Officer of Ironwood Pharmaceuticals, Inc. since 2003 through December 31, 2014 and Senior Vice President until September 02, 2014 respectively. Mr. Higgins served as the Chief Financial Officer of Ironwood Pharmaceuticals, Inc. from June 2003 to September 02, 2014 and served as its Principal Accounting Officer. Mr. Higgins joined Ironwood in 2003. He served a key role Ironwood's evolution, its initial public offering and launch of its first commercial product. He served as Vice President of Corporate Finance at Genzyme Corporation & Genzyme General. He served as the Head of corporate finance, Vice President of Business Development at Genzyme Tissue Repair. He was employed at Genzyme Corporation from 1997 to 2003 in a variety of leadership roles and was involved across multiple business units, including Cell Therapy, Gene Therapy and Orphan Diseases. He served as Chief Financial Officer of Procept, Inc. from 1992 to 1997 and managed the successful IPO of the firm. He began his career in the sales organization of Schering-Plough's Animal Health Division. He serves as a Director of Private Equity Access Fund II, L.P. He serves as a Director of Madauder Therapeutics and Camp4 Therapeutics Corporation (formerly known as Marauder Therapeutics, Inc) since October 2016. He served as a Director of Pulmatrix Operating Company, Inc., from March 2015 to June 15, 2015. He served as a Director of Microbia, Inc. He was the 2014 Boston Business Journal Chief Financial Officer. He is an experienced biotechnology executive and has industry experience. Mr. Higgins holds M.B.A. from the Amos Tuck School of Business Administration at Dartmouth College and a B.S. from Cornell University.

Positions